783TiP - CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation
Autor: | Jimenez Exposito, M.J., Akce, M., Montero Alvarez, J.L., Assenat, E., Balart, L.A., Baron, A.D., Decaens, T., Heurgue-Berlot, A., Martin, A.O., Paik, S.W., Poulart, V., Sehbai, A.S., Takemura, N., Yoon, J.-H. |
---|---|
Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
Databáze: | ScienceDirect |
Externí odkaz: |